Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mass Spectrometry: Complex Analysis01:21

Mass Spectrometry: Complex Analysis

Mass spectrometry is an important technique for the identification of pure compounds. However, it has some limitations for the analysis of complex mixtures, often due to excessive fragmentation making the spectrum too complicated to decipher. Mass spectrometry can be combined with suitable separation methods in sequence, forming hyphenated methods, which are useful in the analysis of complex mixtures.
GC–MS is a powerful hyphenated method commonly used in forensics and environmental...
Tandem Mass Spectrometry01:21

Tandem Mass Spectrometry

Tandem mass spectrometry is a technique that uses multiple mass analyzers in series to obtain a higher selectivity and reduce chemical noise during analyte detection. Instruments with multiple analyzers separated by an interaction cell enable secondary fragmentation and selected study of the fragment ions.Secondary fragmentations occur in the interaction cell and can be induced by various factors. Fragmentation induced by collision with inert gases, such as N2, Ar, He, etc., is called...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predicting median survival from early follow-up data: opportunities, limitations, and extensions.

Journal of the National Cancer Institute·2026
Same author

Anti-LAG-3 with or without anti-PD-1 in recurrent glioblastoma: a phase 1 trial.

Nature medicine·2026
Same author

Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.

Blood·2026
Same author

Immune aging biomarkers for clinical trials.

Nature medicine·2026
Same author

APOE4 Drives Uniquely Dysfunctional Human Microglial States in Alzheimer's Disease.

bioRxiv : the preprint server for biology·2026
Same author

Shrunken Median Location Effect Estimates: An Application to Immuno-Oncology.

Journal of probability and statistics·2026

Related Experiment Video

Updated: Jun 21, 2026

Sample Preparation for Mass Cytometry Analysis
06:28

Sample Preparation for Mass Cytometry Analysis

Published on: April 29, 2017

16.3K

Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC.

Bita Sahaf1, Mina Pichavant2, Brian H Lee3

  • 1Stanford Cancer Institute, Stanford Medicine, Stanford University, California. bsahaf@stanford.edu.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 16, 2021
PubMed
Summary

Harmonizing standard operating procedures and using control samples enabled reproducible cytometry by time of flight (CyTOF) data across multiple Cancer Immune Monitoring and Analysis Centers (CIMAC) laboratories for cancer immunotherapy clinical trials.

More Related Videos

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

9.6K
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

404

Related Experiment Videos

Last Updated: Jun 21, 2026

Sample Preparation for Mass Cytometry Analysis
06:28

Sample Preparation for Mass Cytometry Analysis

Published on: April 29, 2017

16.3K
Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry
12:36

Single-cell Analysis of Immunophenotype and Cytokine Production in Peripheral Whole Blood via Mass Cytometry

Published on: June 26, 2018

9.6K
Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma
08:25

Mass Cytometry Analysis of Systemic and Local Immune Responses in Hepatocellular Carcinoma

Published on: April 25, 2025

404

Area of Science:

  • Immunology
  • Biomarker Discovery
  • Clinical Trials

Background:

  • The Cancer Immune Monitoring and Analysis Centers - Cancer Immunologic Data Commons (CIMAC-CIDC) Network utilizes advanced assays to identify biomarkers for cancer immunotherapy response.
  • Cytometry by time of flight (CyTOF) is a key technology employed across all CIMAC laboratories for these studies.
  • Ensuring data comparability across different sites is crucial for multicenter clinical trials.

Purpose of the Study:

  • To establish a multistep cross-site harmonization process for CyTOF data generation within the CIMAC-CIDC Network.
  • To ensure the ability to generate comparable CyTOF data across all participating CIMAC laboratories.
  • To validate harmonized standard operating procedures (SOPs) and assay protocols, including a new vendor-introduced acquisition protocol.

Main Methods:

  • Harmonization of standard operating procedures (SOPs) across all CIMAC sites.
  • Testing of a new vendor-provided acquisition protocol (wide-bore injector) across sites.
  • Cross-site assay harmonization experiments using shared cryopreserved and lyophilized peripheral blood mononuclear cells (PBMCs) and a standardized antibody cocktail.
  • Centralized data analysis using both manual gating and automated methods (Astrolabe).

Main Results:

  • Achieved an inter-site coefficient of variation (CV) below 20% for most cell subsets, comparable to previous multisite CyTOF studies.
  • Demonstrated successful harmonization of CyTOF assay performance across multiple CIMAC laboratories.
  • Validated the effectiveness of harmonized SOPs and the use of shared control materials.

Conclusions:

  • The implemented cross-site harmonization procedures enable reproducible CyTOF data generation in multicenter clinical trials.
  • Quality control measures, including the use of spike-in control samples, are essential for managing assay variability.
  • These findings support the reliable application of CyTOF for biomarker discovery in cancer immunotherapy research across distributed sites.